7357-26-8 Usage
Uses
Used in Pharmaceutical Industry:
4-chloro-6,7-dimethoxycinnoline is used as a pharmaceutical agent for its anti-inflammatory, anti-cancer, and anti-bacterial properties. Its potential applications in this field are attributed to its ability to modulate various biological pathways and exhibit therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 4-chloro-6,7-dimethoxycinnoline is utilized as a component in the development of pesticides and other agrochemical products. Its biological activities, such as anti-bacterial properties, make it a valuable asset in this industry.
Used in Material Science:
4-chloro-6,7-dimethoxycinnoline also finds applications in material science, where its unique chemical structure and properties can be employed to develop new materials with specific characteristics for various uses.
However, it is important to note that further research is required to fully understand and harness the potential benefits of 4-chloro-6,7-dimethoxycinnoline in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 7357-26-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,3,5 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 7357-26:
(6*7)+(5*3)+(4*5)+(3*7)+(2*2)+(1*6)=108
108 % 10 = 8
So 7357-26-8 is a valid CAS Registry Number.
7357-26-8Relevant academic research and scientific papers
Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors
Yang, Hao,Murigi, Francis N.,Wang, Zhijian,Li, Junfeng,Jin, Hongjun,Tu, Zhude
, p. 919 - 924 (2015/02/19)
Fifteen cinnoline analogues and six benzimidazole phosphodiesterase 10A (PDE10A) inhibitors were synthesized as potential PET radiopharmaceuticals and their in vitro activity as PDE10A inhibitors was determined. Nine out of twenty-one compounds were potent inhibitors of PDE10A with IC50 values ranging from 1.5 to 18.6 nM. Notably, the IC50 values of compounds 26a, 26b, and 33c were 1.52 ± 0.18, 2.86 ± 0.10, and 3.73 ± 0.60 nM, respectively; these three compounds also showed high in vitro selectivity (>1000-fold) for PDE10A over PDE 3A/3B, PDE4A/4B. The high potency and selectivity of these three compounds suggests that they could be radiolabeled with PET radionuclides for further evaluation of their in vivo pharmacological behavior and ability to quantify PDE10A in the brain.
